Galectin Therapeutics (NASDAQ:GALT - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 179.19% from the stock's previous close.
Separately, StockNews.com raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, April 1st.
Get Our Latest Stock Analysis on Galectin Therapeutics
Galectin Therapeutics Price Performance
GALT traded up $0.20 during trading hours on Tuesday, reaching $3.94. 332,158 shares of the stock traded hands, compared to its average volume of 103,202. The firm's fifty day simple moving average is $2.13 and its two-hundred day simple moving average is $1.98. The company has a market cap of $243.90 million, a price-to-earnings ratio of -5.32 and a beta of 0.84. Galectin Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $3.97.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in GALT. Citadel Advisors LLC grew its holdings in Galectin Therapeutics by 269.5% during the 3rd quarter. Citadel Advisors LLC now owns 18,140 shares of the company's stock worth $29,000 after acquiring an additional 28,840 shares in the last quarter. Centaurus Financial Inc. acquired a new position in Galectin Therapeutics during the 1st quarter worth $34,000. Retirement Guys Formula LLC grew its holdings in Galectin Therapeutics by 87.0% during the 4th quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company's stock worth $36,000 after acquiring an additional 10,000 shares in the last quarter. Jane Street Group LLC acquired a new position in Galectin Therapeutics during the 4th quarter worth $40,000. Finally, Beacon Capital Management LLC grew its holdings in Galectin Therapeutics by 89.6% during the 4th quarter. Beacon Capital Management LLC now owns 23,905 shares of the company's stock worth $40,000 after acquiring an additional 11,300 shares in the last quarter. 11.68% of the stock is owned by institutional investors and hedge funds.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Further Reading
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
